U.S., March 19 -- ClinicalTrials.gov registry received information related to the study (NCT06881992) titled 'A Phase 3 Study of Ersodetug in Patients With Tumor-Associated Hyperinsulinism' on March 10.
Brief Summary: The objectives of this study are to evaluate the glycemic efficacy, safety, and tolerability of ersodetug for treatment of hypoglycemia in patients with Tumor-Associated Hyperinsulinism (tHI).
Study Start Date: April, 2025
Study Type: INTERVENTIONAL
Condition:
Tumor- Associated Hyperinsulinism
Intervention:
DRUG: Ersodetug
Ersodetug (9 mg/kg) + SOC
DRUG: Ersodetug
Ersodetug (9 mg/kg) + SOC
DRUG: Placebo
Placebo (9mg/kg) + SOC
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Rezolute
Published by HT Digital Conten...